Latest Conference Articles

A study presented at ACAAI 2025 reveals HAE attacks may start in toddlers, highlighting significant daily burdens and the importance of timely diagnosis and treatment.

Ip highlights the uniform safety of patient-administered etripamil nasal spray across a series of phase 2 and 3 studies.

The SCALE-UP study, assessing patients with atopic dermatitis treated with upadacitinib, points to rapid real‐world efficacy findings on this medication.

New phase 2 data reveals povorcitinib effectively reduces itch and hives in chronic spontaneous urticaria, showing promise as a treatment option.

At the Fall Clinical Dermatology Conference, this session provided clinical pearls to clinicians in the pediatric dermatology space.

Noureddin explains HU6’s mechanism of action and phase 2 data presented at AASLD The Liver Meeting supporting its use in MASH.

Gulati discusses how cardiologists should change their standard care practices to include and educate patients, which will reduce treatment burden and improve adherence.

At ACAAI 2025, Trubiano discusses repurposed immunomodulators, T-cell–targeted approaches, and genetic screening for delayed hypersensitivity management.

Whelton discusses the successful results of an open-label extension investigating GMRx2 (WIDAPLIK), a novel triple combination pill for hypertension.

Alkhouri explains findings from the phase 2 WAYFIND trial suggesting the potential of semaglutide and cilofexor/firsocostat for MASH cirrhosis.

Badimon explains the impact of sotagliflozin’s improvements in left ventricular mass, diastolic function, and 6-minute walk test results in patients without diabetes.

New qualitative findings reveal the underrecognized psychosocial burdens facing children with HAE and the unmet needs shaping their care.

Marston discusses the CORE and CORE2 trials, highlighting olezarsen’s success in lowering fasting triglyceride.

A phase 3b study in patients with skin of color found lebrikizumab provides reliable efficacy and safety for treating moderate-to-severe AD.

New ACAAI 2025 data show lebrikizumab improves disease control, quality of life, and work productivity in patients of skin of color with moderate to severe atopic dermatitis.

Data presented at AASLD 2025 show patients without severe neurologic involvement can achieve cognitive improvement with early detection and therapy.

ASN 2025 VALIANT data on pegcetacoplan show proteinuria reduction, including remission or reduction, in adolescents with C3G and IC-MPGN.

Le discusses the increased risk of mortality and major adverse cardiovascular events in patients with both PAD and AF.

Data from 4 of the most impactful trials presented at the American Heart Association Scientific Sessions 2025.

This Fall Clinical Dermatology Conference interview features Peter Lio, MD, discussing takeaways from several of his sessions at the meeting.

Lau discusses the use of virtual shared medical appointments for increasing access to cardiovascular care in a traditionally underserved population.

Vogelmeier discusses major changes to the annual COPD report, including a broader threshold for escalating treatment after exacerbation.

Here, we spotlighted 4 late-breaker studies featured in our ACAAI 2025 coverage, along with 2 phase 3 trials.

After his sessions on TYK2 Inhibitors for psoriasis and on palmoplantar pustulosis, Vender discussed several key insights in this interview.

COPD is not a complex disease, Polverino explains. It's only complex to treat because of limited understanding.

In this Q&A, Soong discusses phase 2 results on povorcitinib, a JAK1 inhibitor that provides rapid relief from chronic spontaneous urticaria symptoms.

Benjamin Locksin speaks in this interview about his session titled ‘Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis.’

Acoramidis also increased serum transthyretin in patients with wild-type ATTR-CM or the pathogenic variant ATTRv-CM.